Showing 2781 results
-
Ad hoc release /Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du 4e trimestre en hausse de +6% (tcc1, +4% USD) et résultat opérationnel core croissant de +12% (tcc1, +9% USD) Innovative…
-
Press release /Multiple Sclerosis Journal has published data from the ALITHIOS open-label extension study which provide a robust picture of the continuous safety data for Kesimpta, showing it was well tolerated in…
-
Press release /Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo,…
-
Press release /Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers Novartis and Alnylam have agreed to collaborate on discovery and development of…
-
Press release /Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Im vierten Quartal stieg der Umsatz um +6% (kWk1, +4% USD), das operative Kernergebnis wuchs um +12% (kWk, +9% USD) Innovative Medicines steigerte den…
-
Press release /Die Aktionäre genehmigen die 25. Dividendenerhöhung in Folge auf CHF 3.10 (+3,3 %) pro Aktie für 2021; dies entspricht einer Rendite von 3.9 %1 und einer Ausschüttung von rund 57 % des freien…
-
Press release /Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in…
-
Press release /Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-…
-
Press release /In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than…